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HIV fusion inhibitorWe previously identiﬁed a potent small-molecule human immunodeﬁciency virus type 1 (HIV-1) fusion inhibi-
tor, termed ADS-J1, and hypothesized that it mainly targeted the hydrophobic pocket in the gp41 N-terminal
heptad repeat (NHR) trimer. However, this hypothesis has been challenged by the fact that ADS-J1 cannot induce
drug-resistance mutation in the gp41 pocket region. Therefore, we show herein that HIV-1 mutants resistant to
T2635, a peptide derived from the gp41 C-terminal heptad repeat (CHR) region with pocket-binding domain
(PBD), were also resistant to ADS-J1. We also show that pseudoviruses with mutations at positions 64 and 67
in the gp41 pocket regionwere highly resistant to ADS-J1 and C34, another CHR-peptide with PBD, but relatively
sensitive to T20, a CHR-peptide without PBD. ADS-J1 could effectively bind to N36Fd, a mimic of the gp41
NHR-trimer with pocket exposed, and block binding of C34 to N36Fd trimer to form six-helix bundle (6-HB).
However, ADS-J1 was less effective in binding to N36Fd trimer with mutations in the gp41 pocket region, such
as N36(Q64A)Fd, N36(Q64L)Fd, N36(A67G)Fd, N36(A67S)Fd, and N36(Q66R)Fd, as well as less effective in
blocking 6-HB formation between C34 and these mutant N36Fd trimers. These results conﬁrm that ADS-J1
mainly targets the pocket region in the HIV-1 gp41 NHR trimer and suggest that it could be used as a lead for
developing small-molecule HIV fusion inhibitors and as a molecule probe for studying the mechanisms of
gp41-mediated membrane fusion.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Gp41 is the transmembrane subunit of the envelope glycoprotein
(Env) of the human immunodeﬁciency virus type 1 (HIV-1). As such,
it plays a key role in HIV-fusion with, as well as entry into the host
cell, thus serving as an attractive target for developing an HIV-1 fusion
inhibitor. In the early 1990s, we and others identiﬁed several potent
anti-HIV-1 peptides derived from the HIV-1 gp41 C-terminal heptad
repeat (CHR), such as SJ-2176 [18], DP178 (also known as T20) [41]al heptad repeat; Env, envelope
s 1; IC50, concentration causing
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ights reserved.and C34 [31,32] (Fig. 1). T20 (brand name, Fuzeon; generic name,
enfuvirtide) was approved by the U.S. FDA as the ﬁrst HIV fusion inhib-
itor for treatment of HIV/AIDS patients who fail to respond to the cur-
rent antiretroviral drugs. However, its clinical application is limited
because of its poor efﬁcacy and bioavailability necessitating intramuscu-
lar injection twice daily and easy induction of drug resistance [28].
Previous studies have demonstrated that the highly conserved hy-
drophobic pocket in the groove of the gp41 N-terminal heptad repeat
(NHR) trimer plays a critical role in stabilizing the interaction between
the gp41 NHR and CHR, formation of the six-helix bundle (6-HB) core,
and HIV-1 fusion with the target cell, thereby serving as an important
target for development of HIV-1 fusion inhibitors [5,17,34]. The CHR-
peptides with the pocket-binding domain (PBD), such as C34, T2635,
T1144 and CP32M, have much more potent HIV-1 fusion inhibitory ac-
tivity andmuch higher barrier to drug resistance than the CHR-peptides
without the PBD, such as T20 [10,12,15,26,27].
The GIVmotif (residues 36–45: GIVQQQNNLL) in the N-terminal re-
gion of the HIV-1 gp41 NHR is a major determinant of HIV-1 resistance
H
NNNHO
HO3S SO 3H
OCH3
HN
H
NN
NN
OH
N
SO3H
N
SO3H
O CH3
ADS-J1
B
C 
c
f
b
d
CHR
b
f
g
g
a d
e g
a
c
d
e
c
f
b
a
d a
ea
e
g d
ad e
b
g
c
fg
c
cf
bef b
Q64
Q64
Q64
A67
A67 A67
Q66
Q66
Q66
A 
CP COOHNH2
512 684527 542 592 705 856623 663
FP NHR CHR TMloop MPER
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL C34
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF T20
TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL T2635
N36: aa 546-581: SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL
N36Fd(Q66R): SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLRARILGYIPEAPRDGQAYVRKDGEWVLLSTFL
N36Fd(A67S): SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQSRILGYIPEAPRDGQAYVRKDGEWVLLSTFL
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQGRILGYIPEAPRDGQAYVRKDGEWVLLSTFLN36Fd(A67G):
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKLLQARILGYIPEAPRDGQAYVRKDGEWVLLSTFLN36Fd(Q64L):
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKALQARILGYIPEAPRDGQAYVRKDGEWVLLSTFLN36Fd(Q64A):
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILGYIPEAPRDGQAYVRKDGEWVLLSTFLN36Fd: 
GYIPEAPRDGQAYVRKDGEWVLLSTFLFd:
efgabcdefgabcdefgabcdefgabcdefgab
EWDREINNYTSLIHSLIEESQNQQEKNEQE SJ-2176
628 638 648 658
Fig. 1. The HIV-1 gp41 functional domains and the structure of ADS-J1. (A) HIV-1 gp41 and corresponding N- and C-peptide sequences. The residue number corresponds to its position in
HIV-1HXB2 gp160. FP, fusion peptide; NHR, N-terminal heptad repeat (in green), which contains a pocket-forming domain (in brown); CHR, C-terminal heptad repeat (in blue), which con-
tains a pocket-binding domain (in orange); MPER, membrane proximal external region; TM, transmembrane domain; CP, cytoplasmic domain. The amino acid sequences of N-peptides,
and the mutants of N-peptides and C-peptides are shown. (B) Schematic view of the HIV-1 gp41 6-HB core. The letters “a–g” indicate the positions of the corresponding residues in the
helical wheel of the gp41 NHR domain. Residues Q64, Q66, and A67 are located at the c, e, f sites, respectively. Residue Q66 involves direct interaction with the key residues in NHR for
forming N-trimer or those in CHR for forming 6-HB, but not Q64 and A67. The 6-HB is formed through the interaction of residues located at the e and g positions (in red) in the N helices
and those at a and d positions (in green). (C) The schematic representation of the 6-HB (left panel, adapted from ref. 4) and the chemical structure of ADS-J1 contains four sulfonic acid
groups (right panel). The hydrophobic pocket in the groove of NHR-trimer is highlighted by a purple cycle. One of ADS-J1's sulfonic acid groups is expected to interact with the basic
residue K574 in the pocket-forming sequence in NHR.
1297F. Yu et al. / Biochimica et Biophysica Acta 1838 (2014) 1296–1305to CHR-peptides with the GIV-binding domain. Since the major binding
site of T20 is located in this region, HIV-1 variants withmutations in the
GIVmotif isolated from T20-treated patients or T20-containing cell cul-
tures were found to be highly resistant to T20 [4,23,33,36,39,42]. On theother hand, CHR-peptideswithout GIV-binding domain, such as CP32M,
proved highly effective against the T20-resistant strains [15].
We previously identiﬁed the ﬁrst small-molecule HIV fusion inhibi-
tor, termedADS-J1 (Fig. 1), with computer-aided virtual screeningusing
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found that ADS-J1 could directly bind to the gp41 pocket presented on
the IQN17 trimer, block the binding of a short D peptide, PIE7 [11],
to the gp41 pocket, and inhibit 6-HB formation between NHR- and
CHR-peptides [9,38]. Moreover, ADS-J1 could effectively inhibit HIV-1
Env-mediated membrane fusion and HIV-1 replication [9,38]. There-
fore, we proposed ADS-J1 as an HIV fusion inhibitor that mainly targets
the conserved hydrophobic pocket on the gp41NHR-trimer. The ﬁnding
was, however, challenged by Este and colleagues, who concluded that
ADS-JI does not target the gp41 pocket, but rather the gp120, particular-
ly the V3 loop. This conclusionwas based on evidence that ADS-J1 could
induce resistant mutations in the highly variable V3 loop region in
gp120, but not the gp41 pocket region [3,14].
To rebut thisﬁnding and test our hypothesis that themain target site
of ADS-J1 is, in fact, the pocket region in theHIV-1 gp41 NHR-trimer, we
herein assessed the sensitivity to ADS-J1 of HIV-1 strains with muta-
tions in the gp41 pocket and the resistant mutants induced by T2635,
a CHR-peptidewith PBD [12].We found that T2635-resistant HIV-1mu-
tants were also resistant to ADS-J1 and that their resistance to T2635
and ADS-J1was correlated, presumably because theymaymainly target
the same site, i.e., the pocket region in gp41. It was additionally found
that pseudotyped HIV-1 strains with mutations in the gp41 pocket re-
gion (Q64A, Q64L, A67G, A67S, and Q66R) were highly resistant to
ADS-J1 and C34, but relatively sensitive to T20. These results suggest
that similar to the CHR-peptides with PBD, such as T2635 and C34,
ADS-J1 inhibits HIV fusion by mainly targeting the pocket region of
the HIV-1 gp41 NHR-trimer. Therefore, ADS-J1 can be used as a mole-
cule probe for studying the mechanisms of gp41-mediated membrane
fusion and as a lead for developing small-moleculeHIV fusion inhibitors.
2. Materials and methods
2.1. Preparation and titration of HIV Env-pseudoviruses
HIV-1pseudoviruseswithwild-type andmutated Envwere generated
as previously described [30,43]. In brief, the mutations (Q64A, Q64L,
A67G, and A67S) were introduced into the pHXB2-Env by using the
QuikChange® Site-Directed Mutagenesis Kit (Stratagene). The plasmid
encoding wild-type or mutant HXB2-Env was co-transfected with a
plasmid encoding Env-defective, luciferase-expressing HIV-1 genome
(pNL4-3.Luc.R-E-) into HEK293T cells using FuGENE 6 reagents (Roche
Applied Science). The supernatants, which contain the pseudovirions,
were collected 48 h post-transfection, centrifuged at 1000 ×g for
10 min, and ﬁltrated through a 0.45 μm ﬁlter to remove cells. The virions
in the supernatants were concentrated by centrifuging at 26,000 ×g for
2 h, and the concentrations of these pseudovirion stocks were deter-
mined by enzyme-linked immunosorbent assay (ELISA) for p24 antigen
and stored at−80 °C before use.
2.2. Propagation of T2635-resistant HIV-1 variants
The plasmids of one wild-type (HIV-1 LAI molecular clone) and thir-
teen T2635-resistant HIV-1 clones were constructed and propagated as
described before [12]. Brieﬂy, each plasmid (20 μg) was transfected into
HEK293T cells in a six-well plate by using the calciumphosphatemethod.
Supernatants containing T2635-resistant viruses were harvested 72 h
post-transfection. Then the virions in supernatants were further expand-
ed by infecting MT-2 cells. Cytopathic effect (CPE) was observed, and the
supernatantswere collected at days 4, 5, 6, and 7, respectively. The virions
in the supernatants at peak production timewere harvested,ﬁltered, con-
centrated, titrated as described above, and stored at−80 °C before use.
2.3. Determination of infectivity of HIV-1 pseudovirus and HIV-1 LAI clones
An HIV-1 pseudovirus and its mutants (250 ng p24/ml) or HIV-1 LAI
clone and its T2635-resistant mutants (5 ng p24/ml) were preincubatedwith a test compound at indicated concentration at 37 °C for 30 min.
Themixture was added to TZM-Bl cells (1 × 104/well), followed by incu-
bation at 37 °C for 12 h. The culture medium was replaced with fresh
DMEM. After culture for an additional 48 h, the medium was removed.
The cells were washed with PBS and lysed using the lysis reagent from
a luciferase kit (Promega, Madison, WI). The cell lysates were transferred
to 96-well Costar ﬂat-bottom luminometer plates (Corning Costar,
Corning, NY) and luciferase substrate (Promega) was added to the plate,
followed by immediate measuring for luciferase activity (relative light
units, RLU) using an Ultra 384 luminometer (Tecan, USA).
2.4. Construction of vectors encoding N36Fd trimer and its mutants
To construct vectors encoding N36Fd and its mutants, the corre-
sponding DNA fragments in the pseudovirus mutants Q64 (A/L) and
A67 (G/S), as well as the T2635-resistant virus carrying a Q66R muta-
tion, were ampliﬁed by PCR using the Platinum PCR SuperMix High Fi-
delity Kit (Invitrogen) with a forward primer containing a BamH1 site
and a reverse primer coding the ﬁrst 6 amino acids of the Fd fragment.
The DNA fragment of Fd was ampliﬁed by PCR using a forward primer
(the ﬁrst 17 amino acids of Fd) and a reverse primer (the last 17
amino acids of Fd). Then the two overlapping fragments were mixed
and used as templates for another PCR reaction using the BamH1
forward primer and a shorter reverse primer coding the last 8 amino
acids of the Fd with an Xhol1 site. The product was puriﬁed using a
gel extraction kit (Qiagen, Valencia, CA), digested with BamH1 and
Xhol1 enzymes (TaKaRa Bio, Madison, WI), and cloned into a pGEX6p-
1 vector (Qiagen). The sequence was conﬁrmed by DNA sequencing.
2.5. Protein expression and puriﬁcation
N36Fd-trimer-pGEX6p-1 plasmids encoding N36Fd trimer and its
mutantswere transformed into Escherichia coliRosetta 2 (DE3) (Novagen,
Gibbstown, NJ). The cells were incubated at 37 °C in LBmedium until the
A600 reached 0.8–1.0. The culture was induced with 0.1 mM isopropyl
1-thio-β-D-galactopyranoside and incubated at 18 °C for 20 h. Then, the
cells were harvested and broken by sonication in 1% Triton PBS buffer.
After the samples were centrifuged, the supernatant was loaded into a
GST-Bind column (Novagen). The column was rinsed and the bound
GST-fused N36Fd and its mutants were then cleaved with PreScission
Protease (GE Healthcare) in cleavage buffer (50 mM Tris–HCl, pH 7.0,
150 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol) at 4 °C overnight.
The cleaved N-trimer was eluted from the column on the next day by
washing with cleavage buffer. The rough product was further separated
from GST by a series of ultraﬁltrations using Amicon Ultra-15 Centrifugal
Filter Devices (Millipore, Billerica, MA). N36Fd and its mutants became
monomers in the buffer with pH lower than 3.0 and were able to pass
through the 30 kDa Ultra-15 Centrifugal Filter Device and be collected,
while GST that remained in the ﬁlter unit was discarded. After dialysis
against ddH2O (pH 7.0), the monomeric N36Fd and its mutants
were refolded into trimers and concentrated by using a 3 kDa Ultra-15
Centrifugal Filter Device.
2.6. Native polyacrylamide gel electrophoresis (N-PAGE)
N-PAGE was used to detect the inhibitory activity of ADS-J1 on for-
mation of 6-HB between a C-peptide and an N-trimer or its mutant as
described previously [29]. Brieﬂy, the mixture of an N36Fd trimer, or
its mutant (40 μM), and ADS-J1 at an indicated concentration was incu-
bated at 37 °C for 30 min, followed by addition of the C-peptide C34
(40 μM). After incubation at 37 °C for 30 min, the mixture was loaded
onto the 18% Tris-glycine gel (Invitrogen). Gel electrophoresis was car-
ried out at 125 V constant voltage at room temperature for 2 h. The gel
was stained with Coomassie Blue and imaged with a FluorChem 8800
imaging system (Alpha Innotech Corp., San Leandro, CA).
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The secondary structure of N36Fd trimer, or its mutants and resul-
tant complexes, with C34 peptide in PBS (pH 7.2) were determined by
CD spectroscopy as previously described [8,29]. Brieﬂy, the N36Fd tri-
mer, or its mutants (10 μM), were incubated with PBS or ADS-J1
(50 μM) at 37 °C for 30 min, followed by addition of C34 (10 μM).
After further incubation at 37 °C for 30 min, the samples were cooled
to room temperature. The spectra of each sample were acquired on a
spectropolarimeter (Model J-715, Jasco Inc., Japan) at room tempera-
ture, using a 5.0 nm bandwidth, 0.1 nm resolution, 0.1 cm path length,
4.0 s response time, and 50 nm/min scanning speed. The spectra were
then corrected by subtraction of a background corresponding to the
solvent. A [θ]222 value of −33,000 deg cm2 dmol−1 was taken to
correspond to 100% α-helical content as described previously.
2.8. Isothermal titration calorimetry (ITC)
Binding of N36Fd, or its mutant, to ADS-J1 was measured using an
isothermal titration calorimetry instrument (NANO ITC, TA Instruments,
Lindon, UT), which directly measures the heat released or absorbed
during the binding process. ADS-J1 (750 μM) dissolved in PBS (pH 7.2)
was injected into the ITC cell containing 50 μM N36Fd, or its mutant
(pH 7.2). The experiments were carried out at 37 °C. Data acquisition
and analysis were performed using Launch NanoAnalyze software.
3. Results
3.1. T2635-resistant HIV-1 mutants were resistant to T2635 and ADS-J1,
but sensitive to AZT
T2635, a 38-mer CHR peptide with PBD, is a highly potent HIV-1
fusion inhibitor by targeting the gp41 pocket region [10]. This peptide
is highly effective against T20-resistant strains [12]. After 6 months of
culturing T2635 with HIV-1 LAI molecular clone, a series of variants
with single, double and multiple mutations in gp41 were identiﬁed to
be resistant to T2635, suggesting that T2635 resistance is not caused
by mutations in the pocket region, but rather in other regions of gp41
that may alter the kinetics of 6-HB formation, thus limiting the time
window for T2635 to inhibit membrane fusion [12]. Here, we selected
7, 4, and 2 variants with single, double and multiple mutations, respec-
tively, to compare their sensitivity to T2635, ADS-J1, and AZT (an HIV-1
reverse transcriptase inhibitor as a control) with the wild-type (WT)
HIV-1 LAI strain. As shown in Table 1, all the variants with single muta-
tions exhibited moderate resistance to T2635 (4- to 7-fold), while theTable 1
Inhibitory activity of T2635 peptide, ADS-J1 and AZT on infection by T2635-resistant HIV-1 var
Virus T2635 ADS-J1
IC50
(nM)
Resistance
(n-fold)
IC50
(nM)
WT 0.4 ± 0.1 1.0 16.6 ±
A6V 1.9 ± 0.9 4.8 59.4 ±
Q66R 1.9 ± 0.1 4.7 96.5 ±
Q79E 1.6 ± 0.3 4.0 42.5 ±
K90E 2.6 ± 1.4 6.5 52.1 ±
N113E 1.6 ± 0.2 4.2 54.2 ±
N126K 2.7 ± 1.1 6.9 73.4 ±
K154Q 1.5 ± 0.2 3.9 89.8 ±
Q66R N126K 8.6 ± 0.4 21.9 147.3 ±
Q79E N126K 5.2 ± 0.9 13.2 112.1 ±
K90E N126K 7.5 ± 0.9 19.3 108.9 ±
Q66R N113E 8.8 ± 4.3 22.5 120.4 ±
H3C 102.7 ± 46.0 262.7 555.2 ±
H29C 14.2 ± 1.3 36.3 184.7 ±
IC50 values are presented in nM. Results are derived from experiments performed in duplicate a
compared to the IC50 of theWT (HIV-1 LAI clone). H3C is a T2635-resistantHIV-1 variantwithm
T2635-resistant HIV-1 variant with multiple mutations in gp41, including L33S Q66R N113D Nfour variants with double mutations had higher resistance (13- to 23-
fold) than those with single mutation. Those with multiple mutations
were highly resistant to T2635 (36- to 263-fold), which are consistent
with the report by Sanders and colleagues [12]. Similarly, the variants
with single, double and multiple mutations exhibited low, middle and
high resistance to ADS-J1, respectively (Table 1 and Fig. 2A). According
to the fold of resistance as shown in Table 1, resistance of viruses with
single, double and multiple mutations against T2635 is closely correlat-
ed with their resistance against ADS-J1 (r = 0.895, P b 0.01; Fig. 2B).
However, these mutants showed sensitivity to AZT similar to that of
WT to AZT (Table 1). These results suggest that ADS-J1 and T2635
may share a similar mechanism of action, as well as the same target
site in gp41.Mutations in gp41may alter the kinetics of 6-HB formation,
which, in turn, would shorten the time window for T2635 [12] and
ADS-J1 to interfere with HIV-1 gp41-mediated membrane fusion.
3.2. Pseudotyped HIV-1 viruses with mutations of Q64 and A67 in the
pocket region of the gp41 NHR domain were resistant to ADS-J1 and C34,
but relatively sensitive to T20
TheHIV-1 pseudoviruses withmutations at residues Q64 and A67 in
the pocket region of the gp41 NHR domain, both of which are located in
the outer face of the 6-HB (Fig. 1B) and mutations of these residues are
not expected to signiﬁcantly affect the interaction between the viral
gp41 NHR and CHR, were constructed as previously described [30,43].
The inhibitory activity of ADS-J1 on infection by the pseudoviruses
with wild-type Env sequence (WT) and mutations in gp41 (Q64A,
Q64L, A67G, A67S) was determined. As shown in Fig. 3 and Table 2, all
the mutant pseudoviruses were highly resistant to ADS-J1 (30- to 91-
fold increase of IC50 value) and to the PBD-containing CHR peptide
C34 (102- to 210-fold increase of IC50 value), while theywere relatively
sensitive to the CHR peptide T20 without PBD (1- to 5-fold increase of
IC50 value). Similar to C34, these results suggest that ADS-J1maymain-
ly target the pocket region in the HIV-1 gp41 NHR-trimer.
3.3. Decreased inhibitory activity of ADS-J1 on 6-HB core formation
between C34 and N36Fd trimer with mutations in gp41 pocket region
The formation of the 6-HB fusion core is a critical step in gp41-
mediated membrane fusion. Using ELISA and N-PAGE, we have previ-
ously demonstrated that ADS-J1 can block the 6-HB core formation be-
tweenN36 and C34 peptide [19,24,29,38]. Herewe tested the inhibitory
activity of ADS-J1 at graded concentration on the 6-HB formation
betweenC34 peptide andN36Fd trimer, or itsmutants, byN-PAGE anal-
ysis. As shown in Fig. 4A, C34 could form6-HBwithN36Fd trimer and itsiants.
AZT
Resistance
(n-fold)
IC50
(nM)
Resistance
(n-fold)
2.2 1.0 15.1 ± 3.4 1.0
6.3 3.6 8.4 ± 0.6 0.6
5.1 5.8 9.2 ± 6.4 0.6
14.9 2.6 10.3 ± 0.5 0.7
4.6 3.1 11.8 ± 2.1 0.8
1.6 3.3 7.1 ± 2.4 0.5
4.9 4.4 12.8 ± 1.6 0.8
1.8 5.4 13.6 ± 0.7 0.9
29.5 8.9 13.6 ± 2.7 0.9
9.1 6.8 7.5 ± 0.8 0.5
0.6 6.6 6.9 ± 2.0 0.5
33.5 7.3 9.1 ± 7.2 0.6
43.9 33.5 39.0 ± 4.6 2.6
6.5 11.1 7.8 ± 1.7 0.5
nd are representative of at least three independent experiments. Fold resistance is shown
ultiplemutations in gp41, including A6V L33SQ66RN126KH132QE136G;H29C is another
125S N126K H132Q.
r = 0.895, P < 0.01
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Fig. 2. Inhibitory activity of HIV-1 fusion inhibitor on infection of HIV-1 LAI clone and its mutants resistant to T2635. (A) Single-cycle infection experiments using TZM-b1 cells were
performed to test the inhibitory activity of ADS-J1 on infection of the HIV-1 LAI clones with or without mutation. The relative infection activity of each virus clone in the presence of an
inhibitory compound was calculated based on its luciferase activity (relative light units, RLU) in comparison with that of the virus in the absence of the inhibitory peptide. Error bars rep-
resent the standard deviation (SD) from at least three independent experiments. (B) Correlation between the viral resistance to T2635 and resistance to ADS-J. Pearson product–moment
correlation coefﬁcient (r) was calculated using Excel.
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N36(A67S)Fd and N36(Q66R)Fd in the absence of ADS-J1, suggesting
that these mutations do not signiﬁcantly affect the ability of
NHR-trimer to form 6-HB with CHR peptide. However, in the presence
of increasing concentration of ADS-J1, the density of the upper bands
(corresponding to the bands of 6-HBs) became weaker and weaker,
while that of the lower bands (corresponding to the bands of unbound
C34 peptide) became stronger and stronger. For the control N36Fd
trimer, ADS-J1 could completely block the interaction between N36Fd
trimer and C34 at 100 μM binding to the mutant N36Fd trimers and
less potent in blocking (Fig. 4A), while for mutant peptide N36(A67G)
Fd, ADS-J1 could fully inhibit 6-HB formation at 200 or 400 μM
(Fig. 4B–F). These results suggest that ADS-J1 is less effective in 6-HBformation between the C34 peptide and the mutated N36Fd trimers
than wild-type N36Fd trimer.
3.4. Decreased inhibitory activity of ADS-J1 in blocking interaction between
C34 and N36Fd trimer mutants
To further identify the resistance mechanism of ADS-J1, we studied
the properties of NHR-peptide N36Fd trimer and its mutants using CD
spectroscopy. Our previous studies have demonstrated that ADS-J1 signif-
icantly interfered with the interaction between N36 and C34 when ADS-
J1 was mixed with N36 before addition of C34 [38]. In the present study,
we analyzed the secondary structures of the 6-HB formed by the interac-
tion of C34 with N36Fd trimer, or its mutants. Our results demonstrated
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Fig. 3. Inhibitory activity of HIV-1 fusion inhibitor on infection of HIV-1 pseudoviruses ex-
pressing wild-type and mutated gp41. Single-cycle infection experiments using TZM-b1
cells were performed to test the inhibitory activity of ADS-J1 on infection of the viruses
with mutation at the position of 64 (A) and 67 (B) in the gp41 pocket region. The relative
infection activity of each virus in the presence of an inhibitory compound was calculated
based on its relative light units (RLU) in comparison with that of the virus in the absence
of the inhibitory peptide. Error bars represent the standard deviation (SD) from at least
three independent experiments.
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Fig. 4. Dose-dependent inhibition of 6-HB formation by ADS-J1, as assessed by N-PAGE.
N36Fd trimer (A) or its mutants (B–F), and ADS-J1 with graded concentrations from 0
to 400 μM were preincubated at 37 °C for 30 min before addition of C34. The mixture
was then incubated at 37 °C for 30 min. The ﬁnal concentration of the peptides was
40 μM.
1301F. Yu et al. / Biochimica et Biophysica Acta 1838 (2014) 1296–1305that mutations of the residues Q64, A67, and Q66 could affect the confor-
mation and stability of the 6-HB formed by N36Fd trimer and C34, as in-
dicated by the reduced α-helicity of the 6-HBs formed between C34 and
the N36Fd trimerswithmutations (Fig. 5, Table 3). ADS-J1 could interfere
with the interaction between C34 and N36Fd trimer, as shown by theTable 2
The resistance of the NL4-3 variants with mutations in the pocket-forming region of the
HIV-1 gp41 NHR domain to the HIV-1 fusion inhibitors targeting gp41.
Virus ADS-J1 C34 T20
IC50
(nM)
Resistance
(n-fold)
IC50
(nM)
Resistance
(n-fold)
IC50
(nM)
Resistance
(n-fold)
WT 60 ± 0.01 1.0 10 ± 0.01 1.0 17 ± 0.01 1.0
Q64A 3602 ± 0.08 60.0 2100 ± 0.08 210.0 77 ± 0.03 4.5
Q64L 1773 ± 0.06 29.6 1470 ± 0.05 147.0 48 ± 0.02 2.8
A67G 5475 ± 0.09 91.3 2435 ± 0.09 243.5 58 ± 0.02 3.4
A67S 4639 ± 0.08 77.3 1025 ± 0.06 102.5 21 ± 0.01 1.2
IC50 values are presented in nM. Results are derived from experiments performed in
duplicate and are representative of at least three independent experiments.reduction of the α-helicity of the 6-HB formed between C34 and N36Fd
trimer from92.8% to56.2% after the addition of ADS-J1.However, addition
of ADS-J1 to the mixture of C34 and mutated N36Fd trimers caused no
signiﬁcant reduction of α-helicity (Table 3), suggesting that the binding
of ADS-J1 to N36Fd trimer was reduced because of mutations in N36Fd
trimer.
Onemay notice that N36Fd-trimer does not show a typicalα-helical
spectrum, possibly because of the interference of Fd's ß-sheet spectrum
[35] with the α-helical signals of N36-trimer. We previously showed
that subtraction of the ß-sheet spectra of free Fd peptide from that of
N36Fd, a typical α-helical spectrum was revealed [8]. Our previous
studies also demonstrated that N36Fd form stable trimers as deter-
mined by sedimentation velocity and SDS-PAGE analysis. Because
N36Fd can form NHR-trimer, its anti-HIV-1 activity is about 15-fold
higher than the free N36 peptide [8].
3.5. Reduced effectiveness of ADS-J1 in binding of N36Fd trimer with
mutations in gp41 pocket region
We further detected the binding afﬁnity of ADS-J1 to N36Fd trimer
and its mutants by isothermal titration calorimetry. In comparison with
the binding constant of wild-type N36Fd trimer (5.23 × 106 M−1), the
binding constant of ADS-J1 to the ﬁve mutants was reduced about 2–
10-fold (5.68 × 105–1.92 × 106 M−1) (Fig. 6 and Table 4). The titration
experiments revealed that the stoichiometry of the binding of ADS-J1
withN36Fd trimer and itsmutantswas 1.5–2.7:1, rather than1:1, indicat-
ing that about two small molecules interact with one N36Fd trimer or its
mutant.
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Fig. 5. ADS-J1 interferedwith conformational change during the interaction betweenN36Fd trimer, N36Fd trimermutants and C34, as detected by CD spectroscopy. (A) N36Fd trimerwas
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HIV-1 entry into the target cell is initiated by binding of its Env pro-
tein surface subunit gp120 to the primary receptor CD4 and coreceptor,CCR5 or CXCR4, triggering a series of conﬁrmation changes of its Env
protein transmembrane subunit gp41. Such changes involve insertion
of the fusion peptide into the target cell membrane, and formation of
the gp41 NHR-trimer as the transit fusion-intermediate state and the
Table 3
Theα-helical content of N36Fd trimer and its mutants, as well as their mixtures with C34.
N-Peptide [θ] 222 nm(×103) α-Helicity Change of
α-helicity
N36Fd + PBS + C34 –30.6 92.8%
N36Fd + ADS-J1 + C34 –18.5 56.2% 36.6%
N36(Q64A)Fd + PBS + C34 –15.3 46.4%
N36(Q64A)Fd + ADS-J1 + C34 –17.2 52.2% −5.8%
N36(Q64L)Fd + PBS + C34 –15.3 46.4%
N36(Q64L)Fd + ADS-J1 + C34 –13.9 42.2% 4.2%
N36(A67G)Fd + PBS + C34 –14.4 43.9%
N36(A67G)Fd + ADS-J1 + C34 –13.2 40.0% 3.9%
N36(A67S)Fd + PBS + C34 –16.8 50.8%
N36(A67S)Fd + ADS-J1 + C34 –15.2 46.1% 4.7%
N36(Q66R)Fd + PBS + C34 –19.5 59.1%
N36(Q66R)Fd + ADS-J1 + C34 –17.7 53.7% 5.4%
All experiments were performed with 10 μM peptide solutions in phosphate buffered
saline (pH 7.0).
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ing the viral and target cell membranes into close proximity for fusion
[7,21]. A deep hydrophobic pocket (~16-Å long, ~7-Å wide, and 5–6 Å
deep) in the groove on the gp41 NHR-trimer that is formed by a cluster
of conserved hydrophobic residues [6,40] plays an important role in sta-
bilization of the gp41 6-HB formation and gp41-mediated membrane
fusion, as well as HIV-1 replication[5,17,34]. Therefore, this pocket has
been recognized as an attractive target for developing HIV fusion
inhibitors [5,20,25,26].
Using the gp41 pocket as the target in a computer-aided virtual
screening method, together with an ELISA-based gp41 6-HB inhibition
assay, we identiﬁed a small-molecule compound, ADS-J1, which
inhibited HIV-Env-mediated cell-cell fusion and HIV-1 replication at
low μM level [9,19]. The mechanism studies have shown that ADS-J1
binds to IQN17, a trimeric peptide containing the gp41 pocket region,
by conjugating the GCN4 trimerization motif (IQ) with a 17-aa gp41
pocket-forming sequence (N17: aa 564–581) [11], and inhibited bind-
ing of PIE7, a short D peptide [11], with the gp41 pocket on IQN17
[38]. Binding of ADS-J1 to the pocket-containing NHR-peptide could
block 6-HB formation between the NHR- and CHR-peptides [9]. Com-
puter modeling analysis indicated that the negatively charged sulfonic
acid group of ADS-J1 could interact with the positively charged side
chain of K574 in the pocket region, but that the mutation of K574D re-
sulted in the abrogation of ADS-J1 binding to the gp41 pocket region
[38]. All of these results suggest that ADS-J1 mainly targeted the gp41
pocket region.
However, Este and colleagues argued that ADS-J1 targeted neither the
pocket region nor any other regions in gp41. Instead, they hypothesized
that it targets the V3 loop region of gp120 because it failed to induce re-
sistant mutations in the gp41 pocket region, while it could induce resis-
tant mutations in multiple regions of gp120, particularly the highly
variable V3 loop region. These results were based on passage of an HIV-
1 strain resistant to AR177, an anti-HIV-1 polyanionic oligonucleotide
with primary target in gp120, in MT-4 cells for more than 8 months in
the presence of ADS-J1 [3] or the related HIV-1 strains [14]. However,
we are not convinced by their results because they did not use a peptide
or small molecule compound that mainly targets the gp41 pocket as a
control in their experiments. Nevertheless, HIV-1 escape does not neces-
sarily take place at the drug binding site. For example, the CCR5 inhibitor
(vicriviroc) can induce drug-resistant mutations in the fusion peptide
(FP) of gp41 (e.g., M518V or F519L) [2], and some vicriviroc-resistant
HIV-1 strains contain mutations in both FP and NHR domain of gp41
(e.g., M518V, F519L, and V535M) [1].
It has been well recognized that HIV fusion inhibitors targeting the
gp41 pocket have a high barrier to resistance since it is extremely difﬁ-
cult to induce mutations in the gp41 pocket sequence, which is highly
conserved. Moreover, mutation in this region, especially the residues
of the N-helix that line the side chain and right wall of the pocket,might result in the loss of viral function [34]. Indeed, the mutations in-
duced by PBD-containing CHR peptides are not located in the pocket re-
gion of gp41, but rather in other regions in gp41, or even in some
regions responsible for altering 6-HB formation and the time window
of the fusion intermediate state [12,13]. Dwyer et al. obtained an HIV-
1 strain with weak resistance (8.3-fold) to T2544, a PBD-containing
CHR-peptide, after they passaged the viruses in cell cultures in the
presence of T2544 for almost 8 months, while the related mutation
sites could not be deﬁned [10]. Similarly, Eggink et al. passaged T20-
or T1249-resistant HIV-1 in SupT1 T-cell cultures in the presence of
T2635, another PBD-containing CHR-peptide [10] at escalating concen-
trations for 6 months. Several T2635-resistant strains were obtained
with multiple mutations in several gp41 regions, but only one of the
mutations (Q66R) was located in the gp41 pocket region [12]. Interest-
ingly, T2635 could also induce mutations in the V1 and V3 loops of
gp120 (e.g., S148E/I/R and A316T), but cause no substitutions in the pu-
tative gp41-binding sites in gp120, including the C1 and C5 domains
[16,22]. Amutation at the base of the V3 domain in gp120 could partial-
ly compensate for the loss of virus infectivity caused by T2635-resistant
mutations in gp41 [12]. Therefore, the mutations in the V3 loop region
of gp120 induced by ADS-J1, as observed by Armand-Ugon et al. [3],
may also be a strategy used by HIV-1 to compensate for the loss of
viral infectivity caused by ADS-J1-resistant mutations in gp41. Reeves
et al. have observed that gp120/coreceptor afﬁnity is correlated with
sensitivity of coreceptor antagonist and HIV fusion inhibitor T20 since
the enhanced afﬁnity leads to more rapid fusion kinetics and shorter
time window for fusion intermediate state, resulting in reduced sensi-
tivity of the HIV-1 fusion inhibitors targeting the fusion intermediate.
Viruses with mutations in V3 loop and the bridging sheet region of
gp120 that result in gp120's binding afﬁnity for CCR5 exhibited altered
sensitivity to T20 [37].
In the present study, we ﬁrst tested the sensitivity of these T2635-
resistant HIV-1 strains to ADS-J1. Surprisingly, all the T2635-resistant
HIV-1 strains tested were also resistant to ADS-J1 (Table 1, Fig. 2A),
and their resistance to ADS-J1 and T2635 was well correlated
(r = 0.895, P b 0.01, Fig. 2B). These results suggest that ADS-J1 and
T2635 inhibit HIV-1 by a similar mechanism and may share the same
target: the gp41 pocket region. We then constructed 4 HIV-1
pseudoviruses by mutating the residues at position 64 (Q64A or Q64L)
or 67 (A67G or A67S) in the gp41 pocket region, both ofwhich are locat-
ed at the c and f positions, respectively, in the NHR helix wheel. Muta-
tions at these sites are not expected to affect the interaction between
NHR and CHR (Fig. 1B). We previously demonstrated that these HIV-1
mutants retained substantial infection and were highly resistant to the
PBD-containing CHR peptides, such as CP32M, but sensitive to PBD-
lacking CHR peptide, T20 [30,43]. Interestingly, all these mutants were
highly resistant to ADS-J1 and C34, but relatively sensitive to T20
(Table 2 and Fig. 3). Like C34, these data indicate that ADS-J1 inhibits
HIV-1 fusion by mainly targeting the gp41 pocket.
We subsequently constructed a gp41 NHR-trimer by conjugating
the NHR-peptide N36 with a trimerization motif, foldon (Fd), designat-
ed N36Fd, and several mutant N36Fds, including N36(Q64A)Fd,
N36(Q64L)Fd, N36(A67G)Fd, N36(A67S)Fd, and N36(Q66R)Fd. Similar
to the wild-type N36Fd trimer, these NHR-trimers with mutations in
the pocket region could also interact with the CHR-peptide C34 to
form 6-HB. However, the inhibitory activity of ADS-J1 on 6-HB forma-
tion between the mutant NHR-trimer and C34 was lower than that on
the 6-HB formation between the wild-type NHR-trimer and C34 as de-
tected by N-PAGE analysis (Fig. 4). Similarly, the ability of ADS-J1 to in-
terfere with the interaction between wild-type N36Fd trimer and C34
was lower than its ability to interfere with the interaction between
the mutant N36Fd trimer and C34 as determined by CD spectroscopy
(Table 3 and Fig. 5). Furthermore, the binding afﬁnity of the mutant
N36Fd trimer to ADS-J1was lower than that of thewild-type N36Fd tri-
mer as analyzed by isothermal titration calorimetry (Table 4 and Fig. 6).
All of these ﬁndings suggest that the gp41 pocket is the main target of
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Fig. 6. The interaction of ADS-J1 with N36Fd trimer and its mutants. The binding of ADS-J1 to N36Fd trimer (A) and its mutants (B-F) was measured by isothermal titration calorimetry
assay (ITC). Upper panel shows the titration traces when ADS-J1 dissolved in PBS was injected into the N36 solution. Lower panel shows the binding afﬁnity of ADS-J1 to the N36Fd trimer
and its mutants.
1304 F. Yu et al. / Biochimica et Biophysica Acta 1838 (2014) 1296–1305ADS-J1 and that mutations in the pocket region result in the decreased
binding of ADS-J1 to this pocket.
In conclusion, ADS-J1, a small-molecule HIV-1 fusion inhibitor, in-
hibits HIV-1 infection by binding to the conserved hydrophobic pocket
in the gp41 NHR-trimer at the fusion-intermediate state and by
blocking 6-HB fusion core formation between the viral gp41 NHR and
CHR domains. Mutations in the pocket region of gp41 may affect the
pocket-binding activity and HIV-1 fusion inhibitory activity of ADS-J1.
Therefore, this study provides important information for elucidation of
the mechanism of ADS-J1 and suggests that ADS-J1 may serve as alead compound for designing small molecule HIV fusion inhibitors
targeting the gp41 pocket and as a molecule probe for investigating
the fusogenic mechanisms of HIV-1.Acknowledgements
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Table 4
Thermodynamic parameters of ADS-J1 binding to N36Fd trimer and its mutants.
Peptide Molar ratio K(M) ΔG ΔH(KJ/mol) ΔS(J/mol)
N36Fd + ADS-J1 2.610 1.91 × 10−7 −4653.53 −9.20 97.77
N36(Q64A)Fd + ADS-J1 1.639 7.81 × 10−7 −4230.89 −11.84 77.23
N36(Q64L)Fd + ADS-J1 2.299 5.21 × 10−7 −4352.12 −10.66 84.53
N36(Q66R)Fd + ADS-J1 1.550 7.19 × 10−7 −4254.06 −13.13 73.53
N36(A67S)Fd + ADS-J1 1.666 8.70 × 10−7 −4197.80 −12.96 72.55
N36(A67G)Fd + ADS-J1 2.150 1.76 × 10−6 −3985.73 −19.78 43.84
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